pyrroles has been researched along with Muscular Diseases in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 29 (60.42) | 29.6817 |
| 2010's | 17 (35.42) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Bortolotto, LA; de Oliveira, DS; Dos Santos, AM; Hong, VAC; Misse, RG; Pires Borges, IB; Shinjo, SK | 1 |
| Correa, D; Landau, M | 1 |
| Åsberg, A; Bogsrud, MP; Hermann, M; Kringen, MK; Piehler, AP; Retterstøl, K; Stormo, C | 1 |
| Dabrowski, M; Wiliński, J | 1 |
| Laaksonen, R | 1 |
| Awoniyi, O; Gosmanov, AR | 1 |
| Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S | 1 |
| Abdelbaset, M; Agha, AM; Mahmoud, SS; Negm, SA; Safar, MM | 1 |
| Abdulghani, HM; Al-Drees, A; Khalil, MS; Khamis, N | 1 |
| Braathen, P; Molden, E; Skovlund, E | 1 |
| Auster, S; Betteridge, DJ; Colhoun, HM; Demicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Neil, HA; Newman, CB; Szarek, M | 1 |
| Smith, M; Sullivan, D; Wlodarczyk, J | 1 |
| Alt, M; Andrès, E | 1 |
| Abel, T; Fehér, J | 1 |
| Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D | 1 |
| Edholm, B | 1 |
| Famularo, G; Gasbarrone, L; Minisola, G | 1 |
| Brunham, LR; Carleton, BC; Carter, C; Hayden, MR; Hovingh, GK; Jukema, JW; Kastelein, JJ; Lansberg, PJ; Miao, F; Ross, CJ; Stalenhoef, AF; Visscher, H; Zhang, L | 1 |
| Åsberg, A; Bogsrud, MP; Hermann, M; Retterstøl, K; Skottheim, IB | 1 |
| Chacra, AP; Gagliardi, AC; Krieger, JE; Miname, MH; Pereira, AC; Santos, PC; Santos, RD | 1 |
| Teramoto, T | 1 |
| Angelica Merlini, P; Antonietta Demola, M; Ardissino, D; Francesca Notarangelo, M; Guidorossi, A; Marziliano, N; Pigazzani, F | 1 |
| Gropp, C | 1 |
| Arnesen, KE; Bogsrud, MP; Langslet, G; Malt, UF; Ose, L; Retterstøl, K; Sm Stuen, MC; Woldseth, B | 1 |
| Bannykh, S; England, JD; Gray, NL; Haas, RH; Hathaway, S; Kimura, BJ; Phillips, PS; Vladutiu, GD | 1 |
| Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Burmester, JK; Moore, JH; Wilke, RA | 1 |
| McKenney, JM | 1 |
| Clarkson, PM; Hittel, D; Hoffman, EP; Thompson, PD; Urso, ML | 1 |
| Gibson, E; Luo, D; Newman, C; Szarek, M; Tsai, J | 1 |
| Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T | 1 |
| Jellinek, SP; Mahboobi, SK; Rose, M; Shohat, EZ | 1 |
| Asberg, A; Bogsrud, MP; Hermann, M; Mohebi, BU; Molden, E; Ose, L; Retterstøl, K | 1 |
| Guthrie, RM | 1 |
| Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M | 1 |
| Junni, P; Katajamaa, M; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Oresic, M; Päivä, H; Saarinen, L; Seppänen-Laakso, T; Smet, J; Soini, J; Sysi-Aho, M; Van Coster, R | 1 |
| Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P | 1 |
| Molden, E; Westergren, T | 1 |
| Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Rosenberg, L; Uretsky, S | 1 |
| Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Dietz, BL; Oberg, KC | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Bellosta, S; Corsini, A; Paoletti, R | 1 |
8 review(s) available for pyrroles and Muscular Diseases
| Article | Year |
|---|---|
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Albuminuria; Aspartate Aminotransferases; Atorvastatin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Utilization; Female; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pain; Pyrroles; Retrospective Studies | 2006 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Interaction risk with statin switch].
Topics: Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Diltiazem; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Muscular Diseases; Pyrroles; Risk Factors; Simvastatin; Warfarin | 2007 |
The genetic determinants of atorvastatin response.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cholesterol; Genetic Variation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Muscular Diseases; Pyrroles; Risk Factors | 2007 |
Pharmacological interactions of statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Muscular Diseases; Pyrroles; Rhabdomyolysis | 2002 |
9 trial(s) available for pyrroles and Muscular Diseases
| Article | Year |
|---|---|
Safety of Atorvastatin in Patients With Stable Systemic Autoimmune Myopathies: A Pilot Longitudinal Study.
Topics: Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Middle Aged; Muscular Diseases; Pyrroles | 2021 |
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Male; Middle Aged; Muscular Diseases; Practice Guidelines as Topic; Pyrroles; Time Factors; Treatment Outcome; United Kingdom | 2008 |
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2009 |
Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Sensitivity and Specificity | 2011 |
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy.
Topics: Adult; Aged; Antioxidants; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Prospective Studies; Pyrroles; Selenium; Surveys and Questionnaires; Treatment Outcome; Ubiquinone; Vitamins | 2013 |
Statin-associated myopathy with normal creatine kinase levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins.
Topics: Adolescent; Adult; Atorvastatin; Exercise; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle, Skeletal; Muscular Diseases; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitin | 2005 |
A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
Topics: Atorvastatin; Biomarkers; Computational Biology; Gene Expression; Gene Expression Profiling; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Muscle, Skeletal; Muscular Diseases; Pyrroles; Simvastatin; Systems Biology | 2006 |
31 other study(ies) available for pyrroles and Muscular Diseases
| Article | Year |
|---|---|
Ranolazine-induced myopathy in a patient on chronic statin therapy.
Topics: Acetanilides; Aged, 80 and over; Atorvastatin; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Piperazines; Pyrroles; Ranolazine | 2013 |
UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.
Topics: Adult; Alleles; Atorvastatin; Female; Genotype; Glucuronosyltransferase; Heptanoic Acids; Humans; Lactones; Male; Middle Aged; Muscular Diseases; Polymorphism, Genetic; Pyrroles | 2013 |
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Observation; Prospective Studies; Pyrroles; Surveys and Questionnaires | 2013 |
STOMPing forward: statins, muscle complaints and CK.
Topics: Atherosclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Muscle, Skeletal; Muscles; Muscular Diseases; Myalgia; Pyrroles; Randomized Controlled Trials as Topic | 2013 |
Myopathy after switching from brand to generic atorvastatin.
Topics: Aged; Atorvastatin; Blood Chemical Analysis; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Muscular Diseases; Polypharmacy; Pyrroles | 2013 |
A benign tumor as the apparent trigger for myopathy.
Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms | 2014 |
Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.
Topics: Animals; Aorta; Atorvastatin; Biological Products; Combined Modality Therapy; Creatine Kinase; Diet, High-Fat; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Liver; Male; Muscular Diseases; Myocardium; Pyrroles; Rats; Ubiquinone | 2014 |
Does coenzyme-Q have a protective effect against atorvastatin induced myopathy? A histopathological and immunohistochemical study in albino rats.
Topics: Animals; Atorvastatin; bcl-2-Associated X Protein; Creatine Kinase; Cytochromes c; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Muscle, Skeletal; Muscular Diseases; Protective Agents; Pyrroles; Rats; Ubiquinone | 2015 |
Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Topics: Adult; Aged; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscular Diseases; Pyrroles; Risk Management; Simvastatin | 2008 |
[Pubalgia in athlete treated by atorvastatin].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; France; Heptanoic Acids; Humans; Male; Muscular Diseases; Pelvic Pain; Prednisone; Pyrroles; Recurrence; Sports | 2009 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Statin-induced dysphagia].
Topics: Anticholesteremic Agents; Atorvastatin; Deglutition Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles | 2010 |
Comment and reply on: Atorvastatin: safety and tolerability. Statins and polymyositis: a neglected link?
Topics: Atorvastatin; Autoimmune Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Polymyositis; Pyrroles | 2010 |
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Topics: Adult; Aged; Atorvastatin; British Columbia; Case-Control Studies; Chi-Square Distribution; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Netherlands; Odds Ratio; Organic Anion Transporters; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Risk Assessment; Risk Factors; Severity of Illness Index; Simvastatin | 2012 |
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Brazil; Female; Genetic Diseases, Inborn; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles | 2012 |
Genetic predisposition to atorvastatin-induced myopathy: a case report.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles | 2012 |
A piece of my mind: A pain in the tuches.
Topics: Anticholesteremic Agents; Atorvastatin; Buttocks; Cardiovascular Diseases; Heptanoic Acids; Humans; Medication Adherence; Mortality, Premature; Muscular Diseases; Pain; Physicians; Pyrroles; Sciatica; Self Care | 2012 |
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin | 2002 |
Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Base Sequence; Case-Control Studies; Creatine Kinase; DNA Primers; Genotype; Heptanoic Acids; Humans; Muscular Diseases; Pyrroles; Risk Factors | 2005 |
Muscle symptoms associated with statins: a series of twenty patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin | 2006 |
Systemic infections can decrease the threshold of statin-induced muscle injury.
Topics: Acute Kidney Injury; Aged, 80 and over; Atorvastatin; Bacteremia; Enterococcus faecalis; Escherichia coli; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Pyrroles | 2006 |
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Creatine Kinase; Creatinine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Humans; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles | 2006 |
Atorvastatin for stroke prevention.
Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors | 2006 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors | 2006 |
Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation | 2007 |
Physiogenomic association of statin-related myalgia to serotonin receptors.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin | 2007 |
Letter by Rosenberg and Uretsky regarding article, "Risks associated with statin therapy: a systematic overview of randomized clinical trials".
Topics: Atorvastatin; Biomarkers; Creatine Kinase, MM Form; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pain; Pyrroles; Randomized Controlled Trials as Topic; Rhabdomyolysis | 2007 |
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Diagnostic Errors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Simvastatin | 1999 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |